Showing results (151-160 of 280) with videos related to
Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.Blood|October 7, 2024
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemiaMarlise R Luskin, Mark A Murakami, Julia Keating, et al.Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.Experimental Hematology|December 18, 2021
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasmsDebra Van Egeren, Baransel Kamaz, Shichen Liu, et al.Cancer|May 1, 2015
Health care utilization and end-of-life care for older patients with acute myeloid leukemiaAreej R El-Jawahri, Gregory A Abel, David P Steensma, et al.Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.Pageof 28